Evidence map›Paper›PMID 35328203›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Evaluation of FAST COVID-19 SARS-CoV-2 Antigen Rapid Test Kit for Detection of SARS-CoV-2 in Respiratory Samples from Mildly Symptomatic or Asymptomatic Patients.

Immacolata Polvere, Serena Voccola, Silvia D'Andrea, Lucrezia Zerillo, Romualdo Varricchio, Jessica Raffaella Madera, Romania Stilo, Pasquale Vito, Tiziana Zotti

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Immacolata PolvereDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.
Serena VoccolaGenus Biotech, University of Sannio, 82100 Benevento, Italy.
Silvia D'AndreaGenus Biotech, University of Sannio, 82100 Benevento, Italy.
Lucrezia ZerilloDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.
Romualdo VarricchioGenus Biotech, University of Sannio, 82100 Benevento, Italy.ORCID 0000-0003-2288-1868
Jessica Raffaella MaderaDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.
Romania StiloDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.
Pasquale VitoDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.ORCID 0000-0002-5721-7716
Tiziana ZottiDepartment of Science and Technologies, University of Sannio, 82100 Benevento, Italy.

Funding

Ministry of Education, Universities and Research F26C18000160005
6 · The paper itself

Abstract

Molecular tests are the gold standard to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but are associated with a diagnostic delay, while antigen detection tests can generate results within 20 min even outside a laboratory. In order to evaluate the accuracy and reliability of the FAST COVID-19 SARS-CoV-2 Antigen Rapid Test Kit (Ag-RDT), two respiratory swabs were collected simultaneously from 501 patients, with mild or no coronavirus disease 2019 (COVID-19)-related symptoms, and analyzed with both the Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) and the FAST COVID-19 SARS-CoV-2 Antigen Rapid Test. Results were then compared to determine clinical performance in a screening setting. We measured a precision of 97.41% (95% CI 92.42-99.15%) and a recall of 98.26% (95% CI 93.88-99.25%), with a specificity of 99.22% (95% CI 97.74-99.74%), a negative predictive value of 99.48% (95% CI 97.98-99.87%), and an overall accuracy of 99.00% (95% CI 97.69-99.68%). Concordance was described by a Kappa coefficient of 0.971 (95% CI 0.947-0.996). Considering short lead times, low cost, and opportunities for decentralized testing, the Ag-RDT test can enhance the efforts to control SARS-CoV-2 spread in several settings.

Indexed as

Ag-RDTantigenic testCOVID-19diagnosisRT-qPCRSARS-CoV-2surveillance

Identifiers

PMID35328203
PMCPMC8947527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.